MPI and LiPlasome present the phase 1 study with LiPlaCis at the ASCO congress Monday 2 in Chicago at 8am local time

Hoersholm; May 27 2014 – Medical Prognosis Institute A/S (MPI) and LiPlasome Pharma announced today that the phase 1 study with LiPlaCis, where patients are screened for sensitivity in the extension phase using MPI’s Drug Response Predictor technology, will be presented at the General Poster session under Trials in Progress at the annual ASCO conference at the in McCormick Place Convention Center, S Hall A2 in Chicago, Illinois.
“I’m very proud to bring two cutting edge technologies together in this first prospective clinical trial where MPI’s Drug Response Predictor – DRP(TM) will be used to find the cancer patients who will benefit from LiPlaCis. When the optimal dose has been established LiPlaCis will be used in metastatic breast cancer patients who are most sensitive to the product.” Said CEO, Peter Buhl Jensen
In the ongoing LiPlaCis phase 1 study cancer patients are treated with liposomal cisplatin an intelligent technology where cisplatin is encapsulated in lipid bubble that opens when it meets a specific enzyme called sPLA2 at the tumor site. The primary goal is to increase the efficacy of the drug. The DRP uses data from the individual patients own tumor to define whether the patient will be sensitive to LiPlaCis and can be included in the study.
Conference details:
General Poster session Monday June 2nd 8:00am-11:45am
McCormick Place Convention Center, S Hall A2
Poster Board # 229B
Abstract # TPS 1139

About LiPlasome Pharma and LiPlaCis
LiPlasome(TM) Pharma ApS is developing LiPlaCis®, a lipid-based, nano-encapsulated cisplatin drug candidate, designed to selectively target cancer cells and complemented by a proprietary drug response companion diagnostic. LiPlaCis exhibits greater potency and an increased maximum tolerated dose (MTD) compared to cisplatin alone, and will soon progress to a phase 1 / phase 2 extension trial in metastatic breast cancer, having already exhibiting early efficacy in phase 1. LiPlaCis incorporates proprietary targeted lipasome technology, leveraging a novel lipid-based nanoparticle chemistry to address limitations of earlier generation cisplatin formulations; through liposome disruption via tumour selective phospholipase A2-IIA isoenzyme (sPLA2-IIA) hydrolysis, optimised stability and enhanced drug payload capacity and delivery. The LiPlaCis companion diagnostic (Drug Response Predictor) accelerates and de-risks future clinical development and is positioned to provide a value-added commercial diagnostic opportunity.
About DRP
MPI’s lead product DRP (Drug Response Predictor) is a tool to develop tumor-derived gene signatures that may predict which cancer patients are high likely responders to a given anticancer product. The DRP has been tested in 24 trials where 20 trials were positive.  The DRP has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center.
The DRP method can also be used to design the Clinical Development Plan i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patient’s gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients who have a high likelihood of response to the drug. The DRP method can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US in 2013.

About MPI
MPI’s proprietary method can predict patients sensitivity towards a given anticancer drug by its Drug Response Prediction a gene-tests on tumours. MPI’s customers are Pharma and biotech engaged in developing anticancer drugs. MPI’s technology has derived from data from more than 3.000 patient’s tumours and are validated in 24 clinical studies. The test is broadly applicable in all cancer types and for almost all anticancer therapies. The test is believed to be of high value especially for the very large group of cancer patients for whom there are no other bio-markers available.

For further information please contact
CEO Peter Buhl Jensen, Professor, MD, PhD
E-mail: [email protected]
Cell Phone: (+45) 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S